Skip to main content
Click here for updates on LifeSource's response to COVID-19

How is COVID-19 Impacting Donation?

Like many other organizations, LifeSource is experiencing a variety of challenges due to the pandemic, but we still continue our work to save and heal lives through organ, eye and tissue donation.

During this COVID-19 pandemic, the LifeSource team continues fulfilling our mission to save and heal lives through organ, eye and tissue donation. We are, like many other organizations, experiencing a variety of challenges.

Here are some questions and answers about the impact of COVID-19 on the donation and transplantation community:

1. Is LifeSource still fulfilling donation wishes during the pandemic?

Yes. A COVID-19 Command Task Force – led by Julie Kemink, Chief Clinical Officer – meets daily to monitor the changing environment and adjust our practices and guidelines to continue delivering life-saving organs to patients waiting.  LifeSource team members and recovery surgeons continue to be deemed “essential personnel” in hospital facilities and are complying with all requirements while caring for a donor.

2. Are donors being tested for COVID-19?

Yes. On February 6, LifeSource began screening all organ, eye and tissue donors for risk factors utilizing Centers for Disease Control (CDC) criteria. On March 20, LifeSource began testing all potential organ, eye and tissue donors. LifeSource is testing all donors utilizing Food and Drug Administration (FDA) approved testing platforms. Results of screening and testing are shared with transplant centers, tissue processors, and eye processors so they may make an informed decision regarding accepting organs, eyes & tissues for their recipients.

3. Can an individual who tested positive for COVID-19 be a donor? 

Hospitals should continue referring all patients who meet donation trigger criteria so LifeSource can conduct testing. An individual who tested positive with active COVID-19 would not be a viable donor candidate. 

4. How has COVID-19 impacted the donation process?

The donation process has been described as symphony; it takes many people working in concert to make the complex process happen. We are in close communication with our hospital partners, transplant centers, tissue partners, government officials, transportation partners and suppliers regarding needed process adjustments.

Learn more about the donation process.

5. Could the number of donors decrease during this pandemic?

Yes. We are seeing an initial decrease in the total number of potential donors. There are many possible reasons for this including the fact that people are spending less time doing activities outside the home such as working, driving/spending time in vehicles.

Eye donation has also significantly decreased, however recipient needs are being met with the current supply of donor corneas.

6. Has living donation been impacted?

LifeSource leads the coordination of deceased donation while our regional transplant center partners lead in living donation, so we ask that interested parties please contact our transplant center partners for more information on living donation.

7. Are transplant recipients high-risk for COVID-19?

The American Society of Transplantation has published a Transplant Community FAQ resource providing detailed information for transplant recipients regarding COVID-19. As more information becomes available, the document will continue to be updated. Regional transplant centers can also be used as a resource for recipients that have questions in our region.

8. How can I support donation during this time?

Since January 2020, 300 people in the United States have died waiting for a life-saving transplant and more than 110,000 continue to wait. Our work is now more important than ever. You can make a difference by registering as a donor and encouraging others to do the same:

We’ll continue to communicate any developments or new resources that become available. Sign-up for emails to receive future updates.

Related posts: Coronavirus (COVID-19) Update from LifeSource, March 17